Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 513

1.

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Freda PU, Post KD, Powell JS, Wardlaw SL.

J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16.

PMID:
9814451
2.

Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?

Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC.

J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7.

PMID:
12107214
3.

Gender and age in the biochemical assessment of cure of acromegaly.

Freda PU, Landman RE, Sundeen RE, Post KD.

Pituitary. 2001 Aug;4(3):163-71.

PMID:
12138989
4.

Remission criteria for the follow-up of patients with acromegaly.

Gullu S, Keles H, Delibasi T, Tonyukuk V, Kamel N, Erdogan G.

Eur J Endocrinol. 2004 Apr;150(4):465-71.

5.

Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.

Serri O, Beauregard C, Hardy J.

J Clin Endocrinol Metab. 2004 Feb;89(2):658-61.

PMID:
14764777
6.
7.

Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.

Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC.

Horm Metab Res. 2010 Jan;42(1):50-5. doi: 10.1055/s-0029-1239522. Epub 2009 Oct 1.

PMID:
19798623
9.

Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.

Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG.

J Clin Endocrinol Metab. 2001 Jul;86(7):3001-8.

PMID:
11443159
10.

Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.

Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A.

J Clin Endocrinol Metab. 2001 Mar;86(3):1091-8.

PMID:
11238491
11.

Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.

Pekic S, Doknic M, Miljic D, Joksimovic M, Glodic J, Djurovic M, Dieguez C, Casanueva F, Popovic V.

Eur J Endocrinol. 2006 May;154(5):659-66.

12.
13.

Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease.

Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A.

Clin Endocrinol (Oxf). 2007 Apr;66(4):538-42.

PMID:
17371472
14.

Biochemical evidence supporting the Cortina criteria.

von Werder K.

J Endocrinol Invest. 2005;28(11 Suppl International):81-3.

PMID:
16625853
15.

Current concepts in the biochemical assessment of the patient with acromegaly.

Freda PU.

Growth Horm IGF Res. 2003 Aug;13(4):171-84. Review.

PMID:
12914750
16.

Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.

Grinspoon S, Clemmons D, Swearingen B, Klibanski A.

J Clin Endocrinol Metab. 1995 Mar;80(3):927-32.

PMID:
7533774
17.

Growth hormone after oral glucose overload: revision of reference values in normal subjects.

Rosário PW, Furtado MS.

Arq Bras Endocrinol Metabol. 2008 Oct;52(7):1139-44.

18.

Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.

Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G.

Clin Endocrinol (Oxf). 2006 Aug;65(2):250-6.

PMID:
16886969
19.

Evaluation of two highly sensitive assays for serum IGF-1 and GH determination following oral glucose tolerance test in healthy controls.

García de la Torre N, Durán A, de Miguel P, Angel Díaz J, Hervás F, Puente M, Charro A.

Endocrinol Nutr. 2008 Mar;55(3):111-6. Epub 2008 Oct 14. English, Spanish.

PMID:
22967876
20.

Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.

Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ, de Herder WW.

J Clin Endocrinol Metab. 2005 Dec;90(12):6480-9. Epub 2005 Sep 13.

PMID:
16159936

Supplemental Content

Support Center